PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 256 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $712,819 | -3.5% | 23,234 | +26.0% | 0.00% | – |
| Q2 2023 | $738,811 | +0.5% | 18,438 | +2.4% | 0.00% | – |
| Q1 2023 | $734,947 | +6.4% | 18,009 | +0.7% | 0.00% | – |
| Q4 2022 | $690,694 | -26.9% | 17,889 | +0.8% | 0.00% | -100.0% |
| Q3 2022 | $944,335 | -10.1% | 17,754 | -1.4% | 0.00% | 0.0% |
| Q2 2022 | $1,050,100 | -23.9% | 18,012 | -0.4% | 0.00% | 0.0% |
| Q1 2022 | $1,380,018 | +2.5% | 18,082 | -19.2% | 0.00% | 0.0% |
| Q4 2021 | $1,346,000 | +5.7% | 22,371 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $1,273,000 | -14.5% | 22,733 | -7.3% | 0.00% | 0.0% |
| Q2 2021 | $1,489,000 | -11.6% | 24,534 | +2.0% | 0.00% | 0.0% |
| Q1 2021 | $1,685,000 | +11.0% | 24,044 | -5.2% | 0.00% | 0.0% |
| Q4 2020 | $1,518,000 | +3.8% | 25,376 | +4.4% | 0.00% | -50.0% |
| Q3 2020 | $1,462,000 | +14.0% | 24,312 | -1.4% | 0.00% | +100.0% |
| Q2 2020 | $1,282,000 | +46.8% | 24,650 | -5.3% | 0.00% | 0.0% |
| Q1 2020 | $873,000 | -20.9% | 26,027 | +6.8% | 0.00% | 0.0% |
| Q4 2019 | $1,104,000 | +10.1% | 24,375 | -2.8% | 0.00% | 0.0% |
| Q3 2019 | $1,003,000 | -9.1% | 25,072 | -1.2% | 0.00% | 0.0% |
| Q2 2019 | $1,104,000 | +10.5% | 25,382 | -3.3% | 0.00% | 0.0% |
| Q1 2019 | $999,000 | -6.0% | 26,242 | +6.2% | 0.00% | 0.0% |
| Q4 2018 | $1,063,000 | -17.4% | 24,717 | -5.6% | 0.00% | 0.0% |
| Q3 2018 | $1,287,000 | +33.6% | 26,196 | -12.8% | 0.00% | 0.0% |
| Q2 2018 | $963,000 | +3.8% | 30,037 | +0.8% | 0.00% | 0.0% |
| Q1 2018 | $928,000 | -32.3% | 29,802 | -0.7% | 0.00% | 0.0% |
| Q4 2017 | $1,370,000 | +21.9% | 30,013 | +0.3% | 0.00% | 0.0% |
| Q3 2017 | $1,124,000 | -22.3% | 29,934 | -1.2% | 0.00% | -50.0% |
| Q2 2017 | $1,446,000 | +11.5% | 30,307 | +6.6% | 0.00% | 0.0% |
| Q1 2017 | $1,297,000 | +60.7% | 28,435 | +13.8% | 0.00% | +100.0% |
| Q4 2016 | $807,000 | -5.4% | 24,996 | +0.3% | 0.00% | 0.0% |
| Q3 2016 | $853,000 | +1.8% | 24,912 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $838,000 | -31.8% | 24,855 | +2.9% | 0.00% | 0.0% |
| Q1 2016 | $1,229,000 | -33.0% | 24,162 | +1.2% | 0.00% | -50.0% |
| Q4 2015 | $1,834,000 | +88.9% | 23,875 | +1.1% | 0.00% | +100.0% |
| Q3 2015 | $971,000 | -40.2% | 23,625 | +2.8% | 0.00% | -50.0% |
| Q2 2015 | $1,625,000 | -70.0% | 22,978 | -62.3% | 0.00% | -71.4% |
| Q1 2015 | $5,413,000 | -5.8% | 60,920 | -6.0% | 0.01% | -12.5% |
| Q4 2014 | $5,745,000 | +156.4% | 64,797 | +180.2% | 0.01% | +166.7% |
| Q3 2014 | $2,241,000 | +8.2% | 23,128 | +2.6% | 0.00% | 0.0% |
| Q2 2014 | $2,071,000 | +41.1% | 22,546 | +7.5% | 0.00% | +50.0% |
| Q1 2014 | $1,468,000 | +20.9% | 20,976 | -0.7% | 0.00% | 0.0% |
| Q4 2013 | $1,214,000 | +15.7% | 21,125 | -3.1% | 0.00% | 0.0% |
| Q3 2013 | $1,049,000 | +59.4% | 21,793 | -3.9% | 0.00% | +100.0% |
| Q2 2013 | $658,000 | – | 22,676 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |